SML0178

ARL-17477 dihydrochloride hydrate

≥98% (HPLC)

• Synonym(e): N-[4-[2-[[(3-chlorophenyl)methyl]amino]ethyl]phenyl]-2-thiophenecarboximidamide dihydrochloride hydrate
• Empirische Formel (Hill-System): C₂₀H₂₀ClN₃S·2HCl · xH₂O
• CAS-Nummer: 866914-87-6
• Molekulargewicht: 442.83 (anhydrous basis)
• MDL-Nummer: MFCD21608518
• UNSPSC-Code: 12352202
• PubChem Substanz-ID: 329825207
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: powder
• Lagerbedingungen: desiccated
• Farbe: white to beige
• Löslichkeit: H₂O: ≥5 mg/mL
• Ersteller: AstraZeneca
• Lagertemp.: 2-8°C
• SMILES String: O.Cl.Cl.Clc1cccc(CNCCc2ccc(NC(=N)c3cccs3)cc2)c1
• InChI: 1S/C20H20ClN3S.2ClH.H2O/c21-17-4-1-3-16(13-17)14-23-11-10-15-6-8-18(9-7-15)24-20(22)19-5-2-12-25-19;;;/h1-9,12-13,23H,10-11,14H2,(H2,22,24);2*1H;1H2
• InChIKey: QOPATWWWZNTSQF-UHFFFAOYSA-N

Beschreibung

Anwendung

ARL-17477 dihydrochloride hydrate may be used in cell signaling studies.

Biochem./physiol. Wirkung

ARL-17477 is an nNOS specific inhibitor. The IC₅₀ against rat nNOS is 35 nM and it has 100-fold selectivity over endothelial and inducible isoforms. ARL-17477 penetrates the brain, and reduces infarct size and reduces cerebral blood flow in several different rodent models of ischemic brain injury.

Leistungsmerkmale und Vorteile

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Piktogramme: GHS07
• Signalwort: Warning
• H-Sätze: H302,H319
• P-Sätze: P264 - P280 - P301 + P312 - P305 + P351 + P338 - P337 + P313 - P501
• Gefahreneinstufungen: Acute Tox. 4 Oral - Eye Irrit. 2
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable